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Abstract
Background/aims Chronic hepatitis B (CHB) infection is
a serious public health problem due to its potential liver
disease sequelae and highly expensive medical costs such
as the need for liver transplantation. The aim of this study
was to quantify the burden of active CHB in terms of
mortality and morbidity, the eligibility of antiviral
treatment and to assess various treatment scenarios and
possible salvage combinations for cost-effectiveness.
Methods A population cohort from a large data base of
chronic hepatitis B patients was constructed and stratified
according to 10-year age groups, the prevalence of HBsAg,
HBV DNA level, ALT level, HBeAg status and the pres-
ence of cirrhosis. An age-specific Markov model for disease
progression and cost-effectiveness analysis was constructed
and calibrated for the specific population setting.
Results Of about 3.2 million estimated HBsAg carriers,
25 % are eligible for treatment. If the active cohort remains
untreated, 31 % will die due to liver related complications.
Within a 20-year period, 11 % will have developed decom-
pensated cirrhosis, 12 % liver cancer and 6 % will need liver
transplantation. Quality adjusted life years (QALYs) for the
no treatment scenario ranged from 9.3 to 14.0. For scenarios
with antiviral treatment, QALYs ranged from 9.9 to 14.5 for
lamivudine, 13.0–17.5 for salvage therapy, and 16.6–19.0 for
the third generation drugs entecavir and tenofovir.
Conclusion In a country with considerable amount of
active CHB patients, monotherapy with a highly potent
third generation drug has the most health-gain, and is cost-
effective in both HBeAg-positive and negative in all stages
of liver disease.
Keywords Chronic hepatitis B  Cost-effectiveness
analysis  Antiviral therapy  Turkey  Middle income
JEL Classification I18
Introduction
Chronic hepatitis B (CHB) is a major global public health
problem and an important cause of morbidity and mortality
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from sequelae related to CHB which includes cirrhosis
development, decompensation and hepatocellular carci-
noma [1].
Antiviral therapy is the only option to control and pre-
vent progression of disease in chronic patients. The indi-
cations are generally the same for HBeAg-positive and
negative patients. These are based mainly on the combi-
nation of three criteria: serum HBV DNA and ALT levels,
and the stage of liver disease [2].
The course from infection exposure to the development
of complications related to CHB infection may span mul-
tiple decades. Once diagnosed, treatment may modify the
natural course for the better. The American and European
guidelines on treatment of chronic hepatitis B recommend
treatment with pegylated interferon or the nucleos(t)ide
analogs (NA) entecavir or tenofovir [2, 3]. The latter two
NAs are preferred over other NAs because of their antiviral
potency and a high genetic barrier to resistance. However,
treatment options need to be balanced in resource con-
straint settings. It should be of global concern that resource
limitations are especially evident where hepatitis B is
endemic or hyperendemic such as in the Far East or in Sub-
Saharan Africa [4, 5]. The consequences and costs of
treatment strategies may help in contributing to the buildup
of health strategies. Based on its GNI (gross national
income) per capita, every economy is classified as low
income, middle income (subdivided into lower middle and
upper middle), or high income, according to the World
Bank. The GNI per capita for Turkey is $ 9,500, which
classifies Turkey as an upper middle income country. To
support national health authorities policy making in long-
term chronic hepatitis B treatment, we assessed the impact
of treatment in preventing adverse outcomes of CHB
infection, and the cost-effectiveness of various treatment
strategies. For these goals, Turkey was used and investi-
gated as an example median endemic country.
Methods
Cohort definition
A population cohort of CHB patients was constructed from
a recent meta-analysis of age- and region-specific hepatitis
B surface antigen (HBsAg) prevalence in Turkey [6]. We
projected these age-stratified HBsAg prevalence from the
meta-analysis to the total age-specific Turkish population
numbers, which was a total of 71.5 million in 2009 [7].
The HBsAg positive cohort was first divided into two
groups, active and inactive CHB, based on hepatitis B
e-antigen status, HBV DNA level, and serum alanine
aminotransferase (ALT) level. The age-specific distribu-
tions of these factors were derived from a newly
constructed patient database of the gastroenterology
departments of the University of Ankara, and a state hos-
pital in Ankara (Turkiye Yuksek Ihtisas Hastanesi) with
1,453 newly diagnosed CHB patients. Both of these hos-
pital departments receive patients from around the country,
which supposedly means that the constructed patient data is
heterogeneous. In Turkey, almost all CHB cases are
detected at the hospital, of which some patients are coin-
cidentally detected during other medical procedures. The
differentiation of active and inactive CHB is essential since
progression of the disease is different in these two groups.
Patients with high HBV DNA levels HBV DNA
C104 copies/mL and elevated ALT ([2 9 ULN) have
potentially progressive liver disease and are candidates for
HBV antiviral therapy [2], while those with low or unde-
tectable HBV DNA and normal ALT levels usually are
inactive HBsAg carriers with a low risk of disease pro-
gression. Lastly, we classified the active CHB patients into
four categories, namely HBeAg (?) and HBeAg (-) CHB
with or without cirrhosis, respectively, using age group-
specific proportions from large HBeAg-positive and
HBeAg-negative clinical trials [8, 9].
Model and clinical probability estimates
We evaluated the cohort of treatment-naı¨ve active CHB
patients for mortality, morbidity, impact of treatment and
cost-effectiveness of various treatment strategies for a
follow-up time of 20 years, thus the cycle length was 21,
and the half cycle correction was applied with the TreeAge
Pro 2009 software (TreeAge Software, Inc., MA, USA).
The model uses annual probabilities of transition from
CHB to virologic response, and of progression to cirrhosis,
decompensated liver disease or hepatocellular carcinoma,
liver transplantation, and finally death. The natural history
and treatment related annual probabilities are obtained
mostly from systematic reviews (Tables 1, 2) [10–36].
Other causes of death not related to liver disease are
included in the model, as age-specific mortality rates
derived from the Turkish statistics institute [7]. The prob-
abilities of receiving a liver transplant were calculated
based on personal communications with six major liver
transplantation centres distributed throughout Turkey. We
received reports that included annual numbers of liver
transplants due to HBV related decompensated cirrhosis
and HCC. From these figures, we calculated that there are
annually around 500 liver transplantations performed in
Turkey, of which about 150 are for HBV alone (no co-
infections included). Out of these 150 liver transplanta-
tions, 120 are due to decompensated cirrhosis, and 30 to
HCC. This corresponds to an annual probability of
receiving a liver transplant for decompensated cirrhosis of
24 and 6 % for HCC.
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Scenario analysis
The following treatment options used by clinicians in
Turkey were analyzed:
Natural History (no antiviral treatment) scenario: In
this scenario, which is the base case scenario, active CHB
patients progress according to the natural history, fol-
lowing annual rates of progression derived from sys-
tematic reviews (Table 1). Since the disease progression
rates differ among European and Asian cohort studies
[11], we only implemented in the model the annual
progression rates derived from European cohort studies.
We assumed that patients were followed clinically but
did not receive antiviral therapy for CHB. Patients fol-
lowed the natural history according to their HBeAg and
disease status (with or without cirrhosis). Resolution was
defined as seroconversion to anti-HBe in HBeAg positive
patients, and as persistent HBV DNA suppression and
ALT normalization in HBeAg negative patients. We
assumed that all patients received regular ongoing care
once complications occur.
Lamivudine monotherapy scenario: In this scenario,
patients received 100 mg orally once daily with the first
licensed antiviral HBV drug that is associated with a high
incidence of resistance [24]. Such monotherapy is still
being practiced in many countries with limited resources
[5, 37]. We defined sustained virological response (SVR) in
HBeAg positive patients as HBe-antigen loss and devel-
opment of antibodies against HBeAg (anti-HBe).
Entecavir monotherapy scenario: Patients in this strategy
received 0.5 mg entacavir once daily [38, 39]. The treat-
ment related probability estimates are shown in Table 2.
Tenofovir monotherapy scenario: In this scenario
patients received 300 mg of tenofovir for a continuum of
20 years. The annual probability of resistance in this sce-
nario was 0 % for the first and second years of treatment.
Adefovir salvage scenario: In this scenario, patients
initially receive lamivudine. Once resistance occurs,
patients are salvaged add-on by add-on adefovir. Patients
without resistance continued to receive lamivudine.
Tenofovir salvage scenario: In this more up-to-date sce-
nario, patients who have developed resistance during lami-
vudine therapy are switched to treatment with tenofovir [31].
Pegylated Interferon, followed by tenofovir scenario: In
this scenario patients receive 180 mcg/mL of pegylated
interferon once a week subcutaneously, for 48 weeks. If the
patients do not respond or relapse, they start tenofovir in
the following year. The annual transition rates for SVR
after 72 weeks of Peg-IFN was 30 % for HBeAg-positive
and 20 % for HBeAg-negative patients [32–34, 40]. The
withdrawal rate was 2 and 5 % for HBeAg-positive and
negative patients, respectively [35].
Roadmap concept scenario: In this scenario we applied
the ‘roadmap concept’ [41] to the sub-group of CHB non-
cirrhotic HBeAg-negative cases treated with lamivudine,
due to its low price, which continues to be widely used in
HBV endemic areas. Patients with HBV DNA levels
\107 copies/mL start therapy with lamivudine; after
Table 1 Annual transition
estimates of the natural history
of chronic hepatitis B by initial
state
HBV hepatitis B virus
* Ranges are shown in
parentheses
a Estimates derived from
European cohort studies
b The probabilities of receiving
a liver transplantation for
decompensated cirrhosis and
hepatocellular carcinoma were
calculated on the basis of data
from six major transplant
centers in Turkey
Initial state Outcome Estimate (%)* Referencesa
Chronic hepatitis B e? Resolution 6.9 (2.0–23) [10]
Cirrhosis 3.8 (1.6–5.9) [11]
Hepatocellular carcinoma 0.3 (0.3–0.6) [11]
Chronic hepatitis B e- 1.9 (1.0–3.8) [11]
Chronic hepatitis B e- Resolution 1.6 (0.0–11) [10]
Cirrhosis 9.7 (2.9–16.3) [11]
Hepatocellular carcinoma 0.3 (0.3–0.6) [11]
Cirrhosis e? Decompensated cirrhosis 3.9 (2.0–7.9) [12–14]
Hepatocellular cancer 1.8 (0.9–3.8) [12–14]
HBV related death 3.1 (3.1–3.8) [12–14]
Cirrhosis e- Decompensated cirrhosis 2.7 (1.4–5.4) [12–14]
Hepatocellular cancer 2.9 (1.0–5.6) [12–14]
HBV related death 3.1 (3.1–3.8) [12–14]
Decompensated Cirrhosis Liver transplantation 23 (15–25) Personal
communicationb
HBV related death 26 (15–62) [12–14]
Hepatocellular carcinoma Liver transplantation 6 (3.0–7.0) Personal
communicationb
HBV related death 35 (20–60) [10]
Liver transplant HBV related death 6.6 (2.0–12) [10]
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Table 2 Treatment-related annual transition estimates
Initial state Outcome Estimate (%)
Lamivudine Entecavirh Adefovir salvage Tenofoviri Tenofovir salvagej
HBeAg status 1 2 1 2 1 2 1 2 1 2
CHB initial therapya Sustained virological response 20 10 22b 11b 12 10 23 11 19 11
Cirrhosisc 0.5 1.2 0.2 0.6 0.5 1.2 0.2 0.6 0.5 1.2
Hepatocellular carcinomaf 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
CHB long-term therapy Sustained virological response 24 10 27b 11b 12 10 27 11 19 11
Cirrhosisc 0.5 1.2 0.2 0.6 0.5 1.2 0.2 0.6 0.5 1.2
Resistance: year 1 23d 23e 0.1 0.1 6e 6e 0 0 0 0
Year 2 42d 42d 0.3 0.3 21e 21e 0 0 1 1
Year 3 53d 53d 0.4 0.4 21e 21e 0.4 0.4 1 1
Year 4 70d 70d 0.8 0.8 21e 21e 0.8 0.8 1 1
Year 5 74d 74d 1 1 21e 21e 1 1 1 1
Hepatocellular carcinomaf 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
Resistant CHB long-term therapy Sustained virological response 4.5 0 5b 0.5b 4.5 0 5 0.5 5 0.5
Cirrhosisc 2.7 6.2 2.7 6.2 2.7 6.2 2.7 6.2 2.7 6.2
Hepatocellular carcinomaf 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4
Cirrhosis initial therapy Sustained virological response 20 10 22b 11b 12 10 23 12 19 11
Hepatocellular carcinomaf 0.9 1.5 0.9 1.5 0.9 1.5 0.9 1.5 0.9 1.5
Cirrhosis long-term therapy Sustained virological response 24 10 27b 11b 12 10 27 11 19 11
Resistance: year 1 23d 23d 0.1 0.1 60 0 60 0 0 0 0 0
Year 2 42d 42d 0.3 0.3 21e 21e 0 0 1 1
Year 3 53d 53d 0.4 0.4 21e 21e 0.4 0.4 1 1
Year 4 70d 70d 0.8 0.8 21e 21e 0.8 0.8 1 1
Year 5 74d 74d 1 1 21e 21e 1 1 1 1
Decompensated cirrhosis 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9
Hepatocellular carcinoma 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6
Death HBV 2.4 2.4 2.4 2.4 2.4 2.4 2.4 2.4 2.4 2.4
Resistant cirrhosis long-term therapy Sustained virological response 4.5 0 5b 0.5b 4.5 0 5 0.5 5 0.5
Decompensated Cirrhosis 7.9 7.9 7.9 7.9 7.9 7.9 7.9 7.9 7.9 7.9
Hepatocellular carcinoma 1.8 2.9 1.8 2.9 1.8 2.9 1.8 2.9 1.8 2.9
Death HBV 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1
Decompensated Cirrhosis Liver transplantationg 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3
Death HBV 26 26 26 26 26 26 26 26 26 26
Hepatocellular carcinoma Liver transplantationg 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2
Death HBV 35 35 35 35 35 35 35 35 35 35
Liver transplantation Death HBV 6.6 6.6 6.6 6.6 6.6 6.6 6.6 6.6 6.6 6.6
Estimates from Kanwal et al. [10, 15]
a Initial therapy is 12 months (48 weeks) of therapy
b Estimates from recent clinical trials: Chang et al. [16], Lai et al. [17] and Colonno et al. [18]
c Estimates calculated by the author, based on the assumption that the natural progression rates of chronic hepatitis B are reduced by antiviral therapy.
Estimates derived from natural history estimate similar to Kanwal’s assumption of no progression of disease in HBeAg seroconversion, we assume no
progression of disease in case HBV DNA is undetectable by PCR. In the papers from Chang and Lai full suppression of HBV DNA was observed in 80 %
with a high resistance profile drug, and 90 % with a low resistance profile drug. We took these percentages for our calculations. Refs. [16, 17]
d Estimates for Lamivudine resistance from Lai et al. [19] and Moskovitz et al. [20]
e Adefovir salvage resistance estimates from Lee et al. [21], Chen et al. [22] and Yeon et al. [23]
f Estimates based on reduction of progression rates by nucleoside analogue therapy of 50 % Ref. [24]
g The probabilities of receiving a liver transplantation for decompensated cirrhosis and hepatocellular carcinoma were calculated on the basis of data from
six major transplant centres in Turkey
h Estimates for entecavir resistance from Colonno et al. [18, 25] and Tenney et al. [26]
i Tenofovir monotherapy estimates Ref. [27]
j Tenofovir salvage scenario estimates from van Bommel et al. [28], Sarin et al. [29], van Bommel et al. [30] and Reijnders et al. [31]
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24 weeks virologic response on treatment is assessed. If
HBV DNA is undetectable (50 UI/mL, 300 copies/mL),
patients continue their treatment with lamivudine until
resistance or virologic breakthrough occurs, after which
patients are switched to tenofovir. However, if HBV DNA
is above 300 copies/mL at 24 weeks, lamivudine is swit-
ched to tenefovir monotherapy already at week 24. 71 % of
patients are expected to become HBV DNA negative at
week 24 of treatment [42]. Annual resistance rate in these
patients on lamivudine treatment is 2 % [43, 44]. Annual
rate of HBV DNA relapse is 8.2 % (28 % at 4 years) [44].
Model assumptions
An assumption was that HBeAg-positive non-cirrhotic
patients stop treatment after receiving one year consolida-
tion treatment after HBeAg seroconversion and achieving
undetectable HBV DNA levels [2], while HBeAg-negative
patients continue treatment [38] for the follow-up period of
20 years. Also, our model assumes that the resistance for
entecavir and tenofovir scenarios stays low as recent
studies report. After the third year of treatment tenofovir
resistance is assumed to be the same as entecavir. We took
different time points to assess the outcomes for pegylated
interferon and nucleos(t)ide analogues. For the Peg-IFN
scenario we assumed that the non-responders continued
with long-term tenofovir treatment both in HBeAg-positive
and negative patients. For the road map concept the annual
resistance of 2 % estimate was derived from the GLOBE
telbivudine versus lamivudine trial [43].
Cost and utility estimates
Medical costs are obtained from a retrospective analysis of
the medical records of a sample of 542 patients (3,000
hospital admissions), where a random sample of patients
was selected from inactive carriers, CHB active, cirrhosis,
HCC and liver transplantation cases. An average annual
medical treatment cost (excluding antiviral treatment) per
patient in each health state was calculated (unpublished
work). Data extracted for outpatient visits included infor-
mation of visits, diagnosis, type of examination, signs and
symptoms, laboratory tests, and procedures. Outpatients
costs were mainly costs of laboratory tests, examination
and consult. Information for inpatients included the length
of stay, bed costs, surgical procedures, radiation treatment
and chemotherapy. Annual cost was calculated as: cost per
visit 9 visit per year ? costs per admission 9 admission
per year. The costs of antiviral drugs are obtained from the
Turkish Ministry of Health [45]. A wide range of age-
specific health state utilities are obtained from a multi-
national study on chronic hepatitis B [46]. Table 3 contains
Table 3 Annual costs and health state utilities for chronic hepatitis B
Parameter Base-case estimate
TL (€)
(range) References
Drug costs (year 2010 values)
Lamivudine treatment (100 mg) 1,176 (585) 884–1,470 (439–731) [45]
Adefovir salvage treatment (10 mg) 12,012 (5,976) 9,009–15,015 (4,482–7,470) [45]
Entecavir treatment (0.5 mg) 11,292 (5,618) 8,469–14,115 (4,214–7,022) [45]
Tenofovir (300 mg) 8,028 (3,994) 6,021–10,035 (2,996–4,992) [45]
Peg-INF alfa 2a (INJVL 180MCG/ML) 19,344 (9,624) 14,508–24,180 (7,218–12,030) [45]
Medical management costs Personal communicationa
Monitoring of CHB 720 (358) 540–900 (269–627)
Compensated Cirrhosis 1,204 (602) 903–1,505 (452–752)
Decompensated Cirrhosis 5,364 (2,668) 4,023–6,705 (2,001–3,335)
Hepatocellular carcinoma 14,300 (7,114) 10,725–17,875 (5,336–8,892)
Liver transplantation 174,050 (86,592) 130,538–217,562 (64,944–108,240)
Health state utilitiesb
Durable response to treatment 1.00 (0.95–1.00) [46]
Chronic HBV 0.68 (0.66–0.70) [46]
Compensated cirrhosis 0.69 (0.66–0.71) [46]
Decompensated cirrhosis 0.35 (0.32–0.37) [46]
Hepatocellulr carcinoma 0.38 (0.36–0.41) [46]
Liver transplantation 0.67 (0.64–0.69) [46]
CHB chronic hepatitis B, HBV hepatitis B virus
a Obtained from a retrospective analysis of medical records of a sample of 3,000 hospital admissions unpublished work
b See Levy et al. (Ref. [46]) for the age-specific utilities
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the specific cost and utility estimates. All costs and utilities
were discounted at a rate of 3 % per year [47].
Outcomes
By applying the Markov cohort analysis, the cumulative
mortality, and the cumulative probability of developing
cirrhosis, decompensated cirrhosis, HCC, and getting a
liver transplant were quantified for a 20-year time period.
We measured costs (2010 Euro and Turkish Lira), quality
adjusted life years (QALYs), and the incremental cost-
effectiveness ratio (ICER), to determine the additional cost
to obtain one QALY. The guidelines of economic sub-
mission to the BMJ was used for this cost-effectiveness
analysis [48].
Sensitivity analysis
To study the effect of uncertainty of the robustness of our
results, we performed a sensitivity analysis on the low and
high ranges of the transition estimates in the natural history
scenario (Table 1). First, a so called best case scenario was
assessed by applying the high range of achieving sponta-
neous virological response, and the low ranges for the
estimates of disease progression. Second, a worst case
scenario was assessed by applying the low rates for spon-
taneous virological response, and the high ranges for the
disease progression estimates.
We assume that after seroconversion occurs, patients are
allowed a 6 month therapy, and NAs are discontinued. A
recent publication suggests continuation of long-term
nucleos(t)ide analogue treatment, irrespective of the occurr-
ence of HBeAg seroconversion in HBeAg-positive
patients. Following this recent finding, an alternative
scenario was assessed where treatment was continued in
HBeAg-positive patients.
In addition, we performed a Monte Carlo simulation
assuming that all variables followed a triangular distribu-
tion, due to its continues distribution, with base case, low
and high range of values. We simulated 10,000 trials and
plotted the results on cost-effectiveness acceptability curve
stratified by cost-effectiveness thresholds to determine
which treatment to use under different budgetary restraints.
Results
Cohort
Table 4 shows the total population of Turkey in 2009 with
the age-specific prevalence of HBsAg. Around 3.2 million
people (4.6 % of the total population) were estimated to be
HBsAg carriers, with 22.6 % of them having HBeAg-
positive CHB and 77.4 % having HBeAg-negative CHB.
The total number of patients with active CHB was about
828,000 or 25 % of the total HBsAg-positive cohort, of
which 57 % had HBeAg-positive and the rest HBeAg-
negative CHB. The proportion that had cirrhosis in the
active CHB cohort was 13 %.
Mortality and morbidity in the active CHB cohort
The estimated age-specific CHB burden in a 20-year follow
up is shown in Table 5 for the natural history scenario. If
the cohort of 828,347 individuals remains untreated, it is
estimated that 256,788 (31 %) will die due to liver related
complications. Within a 20-year period, 11 % will have
developed decompensated cirrhosis, 12 % HCC and 6 %
Table 4 Age group specific distribution of chronic hepatitis B in Turkey by HBeAg and stage of liver disease
Age group Active CHB Cirrhosis Chronic hepatitis
(no cirrhosis)
(years) Population HBsAg? (%) HBeAg? HBeAg- HBeAg? HBeAg- HBeAg?
(%)
HBeAg-
(%)
HBeAg? HBeAg-
0–14 18,788,587 533,596 (2.84) 283,828 249,768 90,621 47,586 1,818 (2) 2,379 (5) 88,808 45,207
15–24 12,441,662 490,201 (3.94) 176,473 313,729 91,504 45,804 1,830 (2) 2,290 (5) 89,674 43,514
25–34 12,328,944 784,121 (6.36) 159,961 624,160 113,892 132,322 6,834 (6) 9,263 (7) 107,058 123,059
35–44 10,070,734 624,386 (6.20) 62,439 561,947 35,222 96,610 2,466 (7) 14,491 (15) 32,756 82,118
45–54 7,927,348 437,590 (5.52) 22,655 414,935 11,923 74,353 2,981 (25) 20,819 (28) 8,943 53,534
55–64 5,066,402 184,924 (3.65) 12,753 172,170 5,070 41,595 1,673 (33) 21,214 (51) 3,397 20,382
65? 4,893,423 197,205 (4.03) 18,260 178,945 4,565 37,280 0 20,877 (56) 4,565 16,403
Total 71,517,100 3,252,022 (4.57) 736,367 2,515,655 352,797 475,550 17,595 (9) 91,333 (19) 335,202 384,217
CHB chronic hepatitis B, HBeAg hepatitis B e antigen, HBsAg hepatitis B surface antigen
668 M. Toy et al.
123
will need liver transplantation. At the entry into the cohort
in the year 2009, 108,928 (13 %) cases were estimated to
be already in the cirrhotic stage. By the year 2029, another
247,261 (30 %) cases will have developed cirrhosis if left
untreated, and this will have led to a cumulative number of
356,189 (43 %) patients with cirrhosis in the eligible
cohort.
Impact of antiviral treatment on burden of disease
Treating the cohort with lamivudine monotherapy will
decrease the mortality from 256,787 (31 %) to 124,253
(15 %) of cases, and when salvage therapy without delay is
applied once patients become resistant to lamivudine,
mortality will further decrease to 49,700 (6 %) cases. With
the Peg-IFN (followed by tenofovir) strategy mortality will
be reduced to 82,834 (10 %) cases. Treating the same
patients with entecavir or tenefovir monotherapy will
decrease the mortality to 41,417 liver related deaths (5 %).
Cost-effectiveness
A plot of the outcomes of the various strategies on the cost-
effectiveness plane according to HBeAg and disease status
is shown in Fig. 1. The total costs, QALYs gained, incre-
mental QALYs, incremental costs and ICERs for each
scenario are presented in Table 6.
Chronic hepatitis (non-cirrhosis)
The increasing health gain achieved over a period of 20
years for both HBeAg-positive and -negative patients has
been assessed for lamivudine, the roadmap concept (for
HBeAg-negative only), adefovir salvage, tenofovir sal-
vage, pegylated interferon (followed by tenofovir), ente-
cavir and tenofovir therapy strategies.
The natural history (no-treatment) strategy resulted in 14
and 9.3 QALYs and total discounted 20-year CHB related
healthcare costs of 25,781 TL (€12,826) and 48,198 TL
(€23,979) for the HBeAg-positive and negative cohort,
respectively.
Both tenofovir and entecavir had equal incremental
QALYs; however, entecavir compared to tenofovir, in a
20 year follow up period was 11,252 TL (€5,598) and
52,159 TL (€25,949) more expensive in HBeAg-positive
and negative patients, respectively. The incremental cost-
effectiveness ratio (ICER) of tenofovir versus no treatment
was 638 TL (€318) and 15,573 TL (€7,747) for HBeAg-
positive and negative patients, respectively.
CHB (cirrhosis)
The no-treatment strategy resulted in 6.2 QALYs and total
healthcare costs of 104,859 TL (€52,168) and 93,954 TL
(€46,743) for the cirrhotic HBeAg-positive and negative
Table 5 Age-specific clinical outcome of active chronic hepatitis B by HBeAg status in the natural history scenario
HBeAg status n Outcome
Age-group (years) Cirrhosis (%) Decompensated
Cirrhosis (%)
HCC (%) Liver transplant (%) Death (%)
HBeAg?
\15 90,621 819 (1) 863 (1) 1,234 (1) 503 (0,5) 2,574 (3)
15–24 91,504 833 (1) 877 (1) 1,257 (1) 512 (0,5) 2,617 (3)
25–34 113,892 35,401 (31) 12,082 (11) 8,461 (7) 5,776 (5) 27,276 (24)
35–44 35,222 10,966 (31) 3,694 (11) 2,561 (7) 1,769 (5) 8,316 (24)
45–54 11,923 3,783 (32) 1,741 (15) 1,050 (9) 825 (7) 3,842 (32)
55–64 5,070 1,630 (32) 779 (16) 452 (9) 359 (7) 1,689 (33)
65? 4,565 1,574 (34) 241 (5) 206 (5) 109 (2) 526 (12)
All HBeAg? 352,797 55,006 (16) 20,277 (6) 15,221 (4) 9,853 (3) 46,840 (13)
HBeAg-
\15 47,586 424 (1) 680 (1) 1,153 (2) 412 (1) 2,465 (5)
15–24 45,804 406 (1) 657 (1) 1,110 (2) 400 (1) 2,389 (5)
25–34 132,322 99,242 (75) 22,392 (17) 26,464 (20) 11,770 (9) 67,484 (51)
35–44 96,610 73,924 (76) 16,424 (17) 19,322 (20) 8,695 (9) 50,237 (52)
45–54 74,353 54,278 (73) 12,640 (17) 15,614 (21) 6,692 (9) 39,407 (53)
55–64 41,595 28,285 (68) 7,071 (17) 8,319 (20) 3,744 (9) 22,045 (53)
65? 37,280 25,723 (69) 4,846 (13) 5,592 (15) 2,237 (6) 13,794 (37)
All HBeAg- 475,550 323,374 (68) 76,088 (16) 90,355 (19) 38,044 (8) 223,509 (47)
Total 828,347 356,189 (43) 91,118 (11) 99,402 (12) 49,701 (6) 256,788 (31)
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cohort, respectively. The lowest ICER was achieved with
the tenofovir scenario versus no treatment which was 5,328
TL (€2,650) and 6,609 TL (€3,288) in the HBeAg-positive
and negative cohort, respectively.
Sensitivity analysis
The sensitivity analysis for the natural history scenario
shows that, in comparison with the base case, in which the
mortality of the active CHB cohort is 31 %, the mortality
ranges from 17 % in the best case scenario to 42 % in the
worst case scenario. When assessed by subgroups, in the
worst case scenario, mortality ranges from 4 to 28 % for
HBeAg-positive chronic hepatitis, from 8 to 35 % for
HBeAg-negative chronic hepatitis, and from 62 to 91 %
for cirrhosis independent of HBeAg status.
The ICER outcomes analysed when antiviral therapy
were continued irrespective of HBeAg-seroconversion,
varied according to the therapy chosen. Tenofovir and
entecavir monotherapy had an ICER of 22,100 TL
(€11,000) and 36,800 TL (€18,000), respectively. The
ICER for lamivudine monotherapy, lamivudine/adefovir
salvage and lamivudine/tenofovir salvage were, 56,200 TL
(€27,900), 51,200 TL (€25,400) and 26,200 TL (€13,000),
respectively. Pegylated interferon (followed by tenofovir)
had an ICER of 27,600 TL (€13,700).
The World Health Organization defines the threshold
value for intervention cost-effectiveness as three times the
gross national income (GNI) of a country. The threshold
value for Turkey is 47,280 TL (€20,124) [49]. The prob-
abilistic sensitivity analysis indicated that the no-treatment
strategy was preferred at cost-effectiveness thresholds less
than approximately 30,000 TL (€14,925) per QALY, and
tenofovir had the highest probability of being optimal
above this threshold (Fig. 2) for the HBeAg-positive (non-
cirrhosis) patients. For the HBeAg-negative (non-cirrhosis)
patients, tenofovir had the highest probability of being
optimal above 30,000 TL (€14,925) per QALY.
For the HBeAg-positive cirrhotic patients, at a 15,000
TL (€7,462) per QALY threshold, tenofovir had the
greatest net health benefit in 34 % of the simulations, and
pegylated Interferon (followed by tenofovir) in 10 % of the
simulations. In HBeAg-negative cirrhotic patients, tenofo-
vir had a net health benefit of 46 % and pegylated inter-
feron (followed by tenofovir) 14 % at a 15,000 TL (€7,462)
per QALY threshold.
Program costs for treating eligible patients
In addition to the cost and QALY gained per patient, we
calculated the total program costs if the active CHB
patients are identified and treated with the most cost-
Fig. 1 Results of cost-effectiveness analysis stratified by hepatitis B
e antigen (HBeAg) and stage of liver disease: a HBeAg-positive
(non-cirrhosis) b HBeAg-negative (non-cirrhosis) c HBeAg-positive
(cirrhosis) d HBeAg-negative (cirrhosis). Results plotted on a cost-
effectiveness plane. The x-axis represents the gain in QALYs with
each strategy, and the y-axis the total healthcare costs (year 2010
values). NH natural history, Lam lamivudine, Lam ? ADV adefovir
salvage therapy, Peg_IFN ? TDF pegylated interferon followed by
tenofovir, ETV entecavir, TDF tenofovir
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effective strategy. Tenofovir monotherapy had the lowest
ICER for all sub-groups (HBeAg-positive; 638 TL (€318),
HBeAg-negative; 15,573 TL (€7,747), HBeAg-positive
cirrhosis; 5,328 TL, (€2,650), HBeAg-negative cirrhosis;
6,609 TL, (€3,288)), with ICERs far below the 36,212 TL
(€18,016) threshold value. If the total 828,347 active CHB
patients (Table 5) are treated, it will cost about 4.6 billion
TL (€2.3 billion) annually, if not treated the total costs are
tripled due to progression to liver failure and the high costs
of medical treatment (hospitalization) and the need for liver
transplantation.
Discussion
In a country where the estimated number of HBsAg-posi-
tive cases is more than 3.2 million, the total amount of
treatment eligible patients, which was quantified through
Table 6 Base case results of various scenarios: costs, quality adjusted life years (QALYs) gained, incremental QALYs, incremental costs and
incremental cost-effectiveness ratios (ICERs)
Treatment NH* Lam Lam ? ADV Lam ? TDF
HBeAg status ? - ? - ? - ? -
CHB (no cirrhosis)
Cumulative costs
(91,000 TL (€))
25.7 (12.8) 48.2 (23.9) 31.6 (15.7) 72.6 (36.1) 73.4 (36.5) 168.5 (83.8) 54.7 (27.2) 122.5 (60.9)
Cumulative QALYs 14.0 9.3 14.5 9.9 17.0 13.0 17.5 13.8
Incremental costs
(91,000 TL (€))a
– – 5.8 (2.9) 24.4 (12.1) 41.9 (20.8) 120.3 (59.9) 23.2 (11.5) 74.4 (37.0)
Incremental QALYsb – – 0.5 0.6 3.0 3.7 3.5 4.5
ICER (91,000 TL
(€)/QALY)
– – 11.2 (5.5) 38.3 (19.0) 13.9 (6.9) 32.1 (16.0) 6.6 (3.2) 16.3 (8.1)
Cirrhosis
Cumulative costs
(91,000 TL (€))
104.9 (52.2) 93.9 (46.7) 128.1 (63.7) 117.2 (20.1) 205.5 (102.2) 180.0 (89.6) 160.6 (79.9) 154.6 (76.9)
Cumulative QALYs 6.2 6.2 8.1 7.4 13.2 12.9 13.7 13.5
Incremental costs
(91,000 TL (€))a
– – 23.3 (11.6) 23.2 (11.6) 100.7 (50.0) 86.1 (42.8) 55.8 (27.5) 60.6 (30.1)
Incremental QALYsb – – 1.9 1.2 7 6.7 7.5 7.3
ICER (91,000 TL
(€)/QALY)
– – 12.5 (6.2) 20.1 (10.0) 14.5 (7.2) 12.9 (6.4) 7.5 (3.7) 8.3 (4.1)
Treatment Peg INF ? TDF ETV TDF Roadmap
HBeAg status ? - ? - ? - -
CHB (no cirrhosis)
Cumulative costs (91,000 TL (€)) 58.7 (29.2) 161.0 (80.1) 46.0 (22.9) 218.0 (108.5) 34.8 (17.3) 165.9 (82.5) 94.8 (47.1)
Cumulative QALYs 17.5 14.9 18.8 16.6 19.0 16.8 12.2
Incremental costs (91,000 TL (€))a 27.1 (13.5) 112.9 (56.2) 14.4 (7.2) 169.9 (84.5) 3.2 (1.6) 117.7 (58.5) 46.6 (23.2)
Incremental QALYsb 3.5 5.6 4.8 7.3 5.0 7.6 2.9
ICER (91,000 TL (€)/QALY) 7.8 (3.9) 20.0 (9.9) 3.0 (1.5) 23.2 (11.6) 0.6 (0.3) 15.6 (7.8) 15.6 (7.9)
Cirrhosis
Cumulative costs (91,000 TL (€)) 162.9 (81.0) 168.2 (83.7) 218.5 (108.7) 220.8 (109.8) 163.5 (81.3) 163.1 (81.2) –
Cumulative QALYs 14.6 14.3 16.9 16.5 17.2 16.7 –
Incremental costs (91,000 TL (€))a 58.1 (28.9) 74.2 (36.9) 113.6 (56.5) 126.8 (63.1) 58.6 (29.2) 69.1 (34.4) –
Incremental QALYsb 8.4 8.0 10.7 10.3 11.0 10.5 –
ICER (91,000 TL (€)/QALY) 6.9 (3.4) 9.2 (4.6) 10.7 (5.3) 12.3 (6.1) 5.3 (2.6) 6.6 (3.3) –
NH natural history, Lam lamivudine, Lam ? ADV adefovir salvage therapy, Peg_IFN ? TDF pegylated interferon followed by tenofovir, ETV
entecavir, TDF tenofovir
* ‘‘NH (no treatment)’’ was the baseline strategy compared with other treatment strategies
a Difference in costs over NH
b Difference in healthy years over NH
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population data and the large patient database constructed
for this study, is 828,000, and of these, around 108,000 are
patients with liver cirrhosis. If these eligible patients are not
identified and treated, about 12,800 deaths are expected to
occur each year due to liver related complications, leading
to a cumulative number of 256,788 (31 %) in 20 years. The
number of liver transplant patients in Turkey is 400–500 per
year and this treatment is covered by the health insurance
[50]. If we would modestly assume that 50 % of liver
transplantations are due to HBV, there will be a total of
about 4,000 liver transplantations that will take place in
20 years, while the demand will be around 49,000,
according to our estimates. On top of all the life years lost,
and more severe treatment options such as liver transplan-
tation are needed, the 20-year cumulative medical man-
agement cost of an untreated active HBeAg-positive and
HBeAg-negative CHB (no-cirrhosis) patient will be 25,781
TL (€12,800), and 48,198 TL (€23,900), respectively.
If the estimated active CHB cohort is identified and
treated with the most cost-effective drug, liver related
mortality and morbidity can be reduced by almost 80 %.
Comparing treatment scenarios to the no antiviral treat-
ment scenario in all the sub-cohorts, the tenofovir strategy
was the most cost-effective. The ICER for HBeAg-
positive and negative CHB (non-cirrhosis), and HBeAg-
positive and negative cirrhosis was 638 TL (€306), 15,573
TL (€7,800), 5,300 TL (€2,600), and 6,609 TL (€3,300),
respectively. Both entecavir and tenofovir, compared to
the do nothing scenario, had the same amount of health
gain. A recent systematic review and Bayesian meta-
analysis concludes that in the first year of treatment for
CHB, tenofovir and entecavir are the most potent oral
antiviral agents for HBeAg-positive patients, while for
HBeAg-negative patients tenofovir is most effective [51].
According to net sold medication counts per year in
Turkey, it was calculated that no more than 10 % of
active CHB patients receive antiviral treatment [52],
indicating a massive shortcoming in providing eligible
patients with life prolonged and even life saving treat-
ments. At individual level the association of disease
progression with increased cost of disease management
suggests that measures to prevent or delay progression of
CHB related liver diseases will be economically benefi-
cial. At population level, however, the impact of therapy
on the overall number of people with chronic infection
will remain limited as long as the majority of infected
patients will not receive treatment due to lack of recourse
for optimal treatment.
Fig. 2 Cost-effectiveness acceptability curves showing the probabil-
ities of net benefits achieved by each strategy for different willingness
to pay thresholds (the maximum amount a person is willing to pay for
a good) in HBeAg-positive (non-cirrhosis) (a), HBeAg-negative (non-
cirrhosis) (b), HBeAg-positive (cirrhosis) (c), and HBeAg-negative
(cirrhosis) (d). The vertical axes represent the probability of cost-
effectiveness. The horizontal axes represent willingness-to-pay
threshold to gain one additional quality adjusted life year (QALY).
NH natural history, Lam lamivudine, Lam ? ADV adefovir salvage
therapy, Peg_IFN ? TDF pegylated interferon followed by tenofovir,
ETV entecavir, TDF tenofovir
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The future public health burden of chronic hepatitis B
could potentially be reduced by antiviral treatment [53].
The recommendations by the Turkish Association for the
Study of the Liver (TASL) [52] to treat eligible patients are
in line with the European Association for the Study of the
Liver [2] criteria, except that liver biopsy evidence is
always required to start treatment in patients with no
established cirrhosis. Almost all patients are reimbursed for
treatment of viral hepatitis through the national insurance
system in Turkey. A new modification issued in 2009 by
the department within Turkish Health Authorities respon-
sible for reimbursement decisions, states that lamivudine
should be the first line therapy in all patients with viral load
lower than 107 copies/mL. This is largely due to the low
costs of lamivudine and to the recent data about on-treat-
ment monitoring approach, using serum HBV DNA level
as a predictor for efficacy and drug resistance. We assessed
whether this scenario (roadmap concept) was cost-effective
in an HBeAg-negative non-cirrhotic patients group, since
sufficient data were available for this sub-group. The
ICERs of both scenarios, roadmap concept [15,829 TL
(€7,875)] and tenofovir monotherapy [15,573 TL
(€7,747)], were equal. Although eight healthy life years
were gained by tenofovir monotherapy while this was only
three healthy life years gained for the roadmap concept
scenario.
According to our outcomes, the roadmap concept could
be an alternative strategy to consider for a country with a
large HBeAg-negative disease, where tenofovir is not
available. This scenario could also be suggested in resource
poor settings, since the cumulative costs to treat are less
compared to tenofovir monotherapy. Various studies have
examined the cost-effectiveness of antiviral therapy for
CHB and have concluded that treatment is cost-effective
versus no treatment [10, 15, 54–56]. Kanwal et al. [10]
found that lamivudine monotherapy strategy was more
expensive and less effective than treatment with interferon
or salvaged by adefovir. According to our analysis, lami-
vudine monotherapy was less effective as well, but was not
more expensive compared to other treatment strategies.
This can be explained by the fact that more than 5 years
have elapsed between both studies during which the price
of lamivudine has decreased. Buti et al. [57] concludes that
first-line treatment with tenofovir is cost-effective for both
HBeAg-positive and negative patients, in comparison to
other antivirals. They also conclude that tenofovir was
more effective than entecavir, which is in contrast to our
results for which the efficacy equality was equal for both
drugs.
A country with similar patient characteristics and health
care system may benefit from our scenario analysis and
outcomes related to the burden of disease. Considering the
economic affordability in different countries, the cost-
effectiveness thresholds may be different. It may be that in
a country where the threshold is high, a more expensive but
effective drug is cost-effective, while this might not be the
case for this same drug in a country with a lower cost-
effectiveness threshold. A review study by Barbieri et al.
[58] on the generalizability of cost-effectiveness studies
concludes that the differences in cost-effectiveness results
between countries are not systematic, which makes infer-
ences from one country to another difficult.
A limitation of our study is that we used simplified
assumptions (e.g., we did not consider coinfection with
other viruses or toxins such as alcohol that will accelerate
progression), and we assumed the cohort to be static, so
there were no new cases added to the cohort. Also, the
assumption that the development of resistance both with
entecavir and tenofovir for the coming 20 years will stay at
0–1 % per year may underestimate what will happen as
longer term data are collected. We took a rather conser-
vative approach by only including high HBV DNA and
ALT [2 9 ULN. If, like in the guidelines, we had taken
elevated ALT levels but starting at 1 9 ULN, the number
of eligible patients would have increased. Another factor
that surely plays an important role in the estimation of
eligible patients is the inclusion of data from tertiary cen-
tres. In Turkey, data on viral hepatitis are collected at the
provincial health directorate, but only for acute (incident)
cases. Thus, the data on CHB patients is derived from
clinical settings, of which not all patients coming to the
hospital have active disease. Some patients are detected
during the diagnostic process for other diseases and refer-
red to the hepatology department. We conclude that the
cohort data from Turkey are, therefore, likely to be biased
towards more active CHB cases, which could mean that the
number of eligible patients might be an overestimation.
One way to account for this bias would be to implement
new information systems and registries to facilitate the
notification, counseling, and medical management of per-
sons with CHB infections in countries with intermediate or
high endemicity. Any attempt to predict the future is likely
to be biased. Therefore, our projections and estimates
regarding future treatment rates and liver-related deaths are
only intended to provide a crude overview of the public
health impact of antiviral therapy.
Identification of chronic hepatitis B infected individuals
is essential to ensure that infected persons receive neces-
sary care to prevent or delay onset of significant liver
disease and services to prevent transmission to others.
Achieving identification could be done by monitoring
inactive cases annually, as is recommended in the guide-
lines. Antenatal screening should be routinely performs,
and new information systems and registries should be
implemented to facilitate the notification, counselling, and
medical management of persons with chronic HBV
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infection in countries with intermediate and high ende-
micity. Given the substantial mortality and morbidity
attributable to HBV related chronic liver diseases, the
control of progression to cirrhosis, decompensated cirrho-
sis and liver cancer will continue to be an important public
health priority. Third generation drugs, such as entecavir
and tenofovir, with high effectiveness and low resistance
profiles, should be made more affordable to help people
with active chronic hepatitis B lead healthier lives.
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